BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Andrea Apolo
with the dual primary endpoint of disease-free survival and overall survival. So we reported the outcomes of the disease-free survival and we found a doubling of the disease-free survival with adjuvant pembrolizumab. So it went from 14.2 months with observation to 29.6 months in the patients receiving pembrolizumab. So this was really exciting.
0
💬
0
Comments
Log in to comment.
There are no comments yet.